<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4919">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193020</url>
  </required_header>
  <id_info>
    <org_study_id>ST-859</org_study_id>
    <nct_id>NCT04193020</nct_id>
  </id_info>
  <brief_title>Acute and Chronic Inflammatory Disease, Lifestyle and Treatment Response</brief_title>
  <acronym>ACID LTR</acronym>
  <official_title>Impact of Lifestyle and Treatment on the Recurrency and Severity of Acute and Chronic Inflamatory Eye Diseases: Protocol on Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wrocław University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wroclaw Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute and chronic inflammatory eye diseases are difficult to diagnose and maintain quiescent&#xD;
      with therapy. Proposed study is aimed to find on the one hand, novel factors for recurrence&#xD;
      of the disease or remission of inflammation and evaluation of the impact of lifestyle and&#xD;
      known factors on the other.&#xD;
&#xD;
      Each patient is treated in accordance to the best of medical knowledge and guidelines for&#xD;
      each disease.&#xD;
&#xD;
      This prospective cohort study will enroll uveitic patients to the steroid only group (SG),&#xD;
      combined (steroid and adjuvant drug) group (CG) or bilogic therapy group (BTG).&#xD;
&#xD;
      At baseline, patient data are recorded using patient-reported outcome measures and clinical&#xD;
      assessments (ophthalomology) on disease activity (clinical scales), quality of life, and&#xD;
      lifestyle together with registry data on comorbidity and medication. During follow-up&#xD;
      evaluation of a successful treatment outcome response will be based on clinical scales and&#xD;
      most frequently used primary endpoints; the major outcome of the analyses will be to detect&#xD;
      differences in treatment outcome between patients in different treatment group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Treatment success</measure>
    <time_frame>1 year</time_frame>
    <description>Total number of treatment success in each group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence time</measure>
    <time_frame>10 years</time_frame>
    <description>Time to the next recurrence after the treatment regimen introduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe visual loss</measure>
    <time_frame>10 years</time_frame>
    <description>Time and cause of severe visual loss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ETDRS Visual Acuity</measure>
    <time_frame>10 years</time_frame>
    <description>Visual Acuity will be performed with ETDRS charts different for right and left eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The SUN working group grading system for anterior chamber cells</measure>
    <time_frame>10 years</time_frame>
    <description>At each visit anterior chamber will be examined to assess anterior chamber cells (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°). The recorded number of cells will be used to determine the grade according to the SUN criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The SUN working group grading system for anterior chamber flare</measure>
    <time_frame>10 years</time_frame>
    <description>At each visit anterior chamber will be examined to assess anterior chamber flare (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°). The observed changes will be used to determine the grade according to the SUN criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AREDS 2008 Clinical Lens Opacity Grading Procedure</measure>
    <time_frame>10 years</time_frame>
    <description>Using AREDS system for classifying cataracts from photographs: AREDS Report No. 4 the lens opacity will be graded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH grading system for vitreous cells</measure>
    <time_frame>10 years</time_frame>
    <description>At each visit vitreous will be examined to assess vitreous cells (1mm x 3mm slit beam in anterior vitreous). The recorded number of cells will be used to determine the grade according to the NIH criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH grading system for vitreous haze</measure>
    <time_frame>10 years</time_frame>
    <description>At each visit vitreous will be examined to assess vitreous haze. The recorded of clarity of posterior pole funduscopy will be used to determine the grade according to the NIH criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Submacular choroidal thickness</measure>
    <time_frame>10 years</time_frame>
    <description>OCT EDI recordings processed with developed by researchers methodology for image processing.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>COVID-19 confirmed infection asymptomatic patient</measure>
    <time_frame>1 year</time_frame>
    <description>PCR-positive result of COVID-19 specific testing, no treatment required</description>
  </other_outcome>
  <other_outcome>
    <measure>COVID-19 confirmed infection</measure>
    <time_frame>1 year</time_frame>
    <description>PCR-positive result of COVID-19 specific testing, patient require treatment. The mode of treatment will be recorded into several groups: 1) antibiotics, 2) antivirals, 3) biologic treatment, 4) immunoglobulins, 5) steroids</description>
  </other_outcome>
  <other_outcome>
    <measure>COVID-19 related acute respiratory distress syndrome (ARDS)</measure>
    <time_frame>1 year</time_frame>
    <description>COVID-19 related acute respiratory distress syndrome (ARDS). Situation in which patients need any of described below: 1) supportive oxygen therapy, 2) non-invasive ventilation, 3) invasive/ mechanical ventilation, 4) use of ECMO, 5) admission to intensive care unit, 6) dialysis</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>steroid only group (SG)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>combined (steroid and adjuvant drug) group (CG)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>bilogic therapy group (BTG)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surveillance card</intervention_name>
    <description>Surveillance card and additional examination to find novel markers and better assess the existing ones</description>
    <arm_group_label>bilogic therapy group (BTG)</arm_group_label>
    <arm_group_label>combined (steroid and adjuvant drug) group (CG)</arm_group_label>
    <arm_group_label>steroid only group (SG)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient with a new diagnosis or a recurrence of uni or bilateral uveitis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  new diagnosis of uni or bilateral uveitis&#xD;
&#xD;
          -  recurrence of the diagnosed previously uni or bilateral uveitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not mentally able to reply the questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Misiuk-Hojło, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Wrocław</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Przeździecka-Dołyk, PhD</last_name>
    <phone>+49605693022</phone>
    <email>joanna.przezdziecka-dolyk@umed.wroc.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology</name>
      <address>
        <city>Wrocław</city>
        <zip>54-622</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Przeździecka-Dołyk, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 7, 2019</study_first_submitted>
  <study_first_submitted_qc>December 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wroclaw Medical University</investigator_affiliation>
    <investigator_full_name>Joanna Przeździecka-Dołyk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Sharing coded data such as BCVA, intraocular preassure, visual functioning questionaire responses, anterior chamber cells and flare scales records as well as lens opacity grading records.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

